AST SpaceMobile Gains as Market Approval Signals New Phase in Satellite Communications
Shameful UK Welfare Spending on Benefits Over Jobs for Young People Says Alan Milburn Calls for System Reform
Grenfell Prosecution Recommendations Signal Potential Financial Repercussions for Construction and Insurance Sectors
Japan Hotel Rates Hit Record as Western Tourists Fill Gap Left by Chinese Visitors
Disneys The Mandalorian and Grogu Opens to 82M Lowest in Star Wars Franchise History
T Rowe Prices Tony Wang Shifts AI Focus to Space and Photonics After Early Nvidia Success
CREX Q1 2026 Earnings EPS Falls Sharply Below Estimates Despite Positive Stock Reaction
RILYL Q1 2024 Earnings Preferred Stock Reports Negative EPS Amid Market Challenges
TLPH Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Stock Reaction
Northpointe Bancshares Inc NPB Q1 2026 Earnings EPS Misses Estimates Shares Dip in First Report as Public Company
Certara Q1 2026 Earnings EPS Misses Estimates Stock Rises on Optimism
RH Q1 2026 Earnings EPS Misses Estimates Stock Declines Amid Luxury Market Challenges
Simulations Plus SLP Surges 268 as Shares Approach 1569 Resistance Zone
CeriBell CBLL Edges Lower Hovers Near Support Amid Modest Decline
XCF Global SAFX Edges Lower as Stock Tests Key Support Levels
Telesat TSAT Surges Over 8 as Bullish Momentum Builds Toward Key Resistance
Psyence Biomedical PBM Rallies 585 as Shares Test Key Resistance Near 456
Cruise Stocks Rally Carnival and Norwegian Surge on MeanReversion Royal Caribbean Lags Behind
Prediction Markets Surge in Popularity Among Young Men as Industry Reaches MultiBillion Dollar Valuation
BUDA Q1 2026 Earnings Earnings Beat Estimates by 634 as EPS Surges to 005
AGCO Q1 2026 Earnings Massive EPS Beat Masks Broader Market Concerns
SoftBank Group Shares Extend Rally Surging Over 11 on AI and Arm Stakes
Billionaire Stanley Druckenmiller Invests 3387 Million in Caris Life Sciences During Q1
Qualcomm Stock Surges as Investors Wake Up to AI Device Boom Potential
ESLA Q1 2026 Earnings WiderThanExpected Loss and No Revenue Highlight DevelopmentStage Challenges
Stoke Therapeutics STOK Sees Minor Decline as Shares Test Support Near 28 Level